Daily Archives: January 18, 2018

Immuno-checkpoint inhibitor (ICI) is becoming an integral part of advanced cancer treatment. ICI can cause adverse events in multiple organs more commonly in skin and GI tract. ICI-induced colitis (ICI-C) can be mild or severe and lead to cessation of … Continue reading →

The relationship between sleep disturbances and inflammatory conditions is incompletely understood. Studies have shown that inflammatory bowel disease (IBD) patients have poorer sleep quality, prolonged sleep latency and increased use of sleeping pills… Continue reading →

Inflammatory bowel disease (IBD) is a chronic condition characterized by periods of remission and relapses. Periodic surveys are used to monitor disease activity but are limited by their length and reliance on subjective recall. We assessed the feasibi… Continue reading →

Treatment options for inflammatory bowel disease (IBD) have expended tremendously in the past two decades. Biologics have now been increasingly used early in the course of therapy with the goal of inducing remission and thus delaying or avoiding the n… Continue reading →

Due to the complexity of diagnosis and treatment of Inflammatory bowel disease (IBD), providers observe a large volume of patient inquiries at the Call Center, resulting in a significant investment of time on the part of the providers and support staff… Continue reading →

Rituximab (RTX), an anti-CD20 monoclonal antibody used in treatment of hematologic and rheumatologic disease, depletes systemic and intestinal B-cells. Diarrhea is seen in ∼15% of people. Case reports associated RTX with de novo inflammatory bowel di… Continue reading →

Hypercalcemia has been described in patients with many granulomatous diseases. Elevated serum calcium levels in the setting of granulomatous disease are caused by unregulated production of 1,25-dihydroxyvitamin D by activated macrophages. More commonly… Continue reading →

Lean body mass (LBM) deficits in youth with Inflammatory Bowel Disease (IBD) are well-established and persist despite achievement of remission and restoration of body mass. LBM deficits are associated with both short and long-term health outcomes inclu… Continue reading →

Studies regarding long-term outcomes of adalimumab treatment in non-Caucasian patients with ulcerative colitis (UC) are still lacking. Continue reading →

We have previously demonstrated that gene deletion of the immunosuppressive enzyme IDO1 (indoleamine-2,3-dioxygenase 1) reduces but does not eliminate tumor burden in a mouse model of colitis associated cancer (CAC). In the current study, we test the h… Continue reading →